Good or evil: CD26 and HIV infection

Journal of Dermatological Science

Volumn 22, Issue 3, 2000, Pages 152-160

  Ohtsuki, Takashi ^a   Tsuda, Hidetoshi ^a   Morimoto, Chikao ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

CD26 dipeptidyl peptidase IV; Chemokines; HIV infection

Indexed keywords

ADENOSINE DEAMINASE; CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; GLYCOPROTEIN; RANTES;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOTAXIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRULENCE;

EID: 0033956421     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(99)00081-X     Document Type: Article

References (62)

1. Geppert T.D., Davis L.S. et al. Accessory cell signals involved in T cell activation. Immunol. Rev. 117:1990;5-66.
2. Dang NH, Torimoto Y et al. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 1990:144: 4092-4100.
3. Morimoto C., Torimoto Y. et al. 1F7, a novel cell surface molecule involved in helper function of CD4 cells. J. Immunol. 143:1989;3430-3439.
4. Torimoto Y., Dang N.H. et al. Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol. Immunol. 29:1992;183-192.
5. Hegen M., Niedobitek G. et al. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J. Immunol. 144:1990;2908-2914.
6. Tanaka T., Kameoka J. et al. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA. 90:1993;4586-4590.
7. Tanaka T., Camerini D. et al. Cloning and functional expression of the T cell activation antigen CD26. J. Immunol. 149:1992;481-486.
8. Torimoto Y., Dang N.H. et al. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J. Immunol. 147:1991;2514-2517.
9. Kameoka J., Tanaka T. et al. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 261:1993;466-469.
10. Morrison M.E., Vijayasaradhi S. et al. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J. Exp. Med. 177:1993;1135-1143.
11. Dong R.-P., Kameoka J. et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J. Immunol. 156:1996;1349-1355.
12. Valle-Blazquez M., Madueño J.A. et al. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J. Immunol. 149:1992;3073-3077.
13. Schenittman S.M., Lane H.C. et al. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl. Acad. Sci. USA. 87:1990;6058-6062.
14. Morimoto C., Lord C.I. et al. Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apotosis. Proc. Natl. Acad. Sci. USA. 91:1994;9960-9964.
15. + T lymphocytes of HIV-infected subjects. J. AIDS. 6:1993;749-757.
16. + T-cell subset during HIV infection. Res. Immunol. 147:1996;5-8.
17. + T cells expressing relatively high levels of CD26. Exp. Cell Res. 241:1998;352-362.
18. Westendorp M.O., Frank R. et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 375:1995;497-500.
19. Kristiansen T.B., Knudsen T.B. et al. Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Scand. J. Immunol. 48:1998;339-346.
20. Riley J.L., Levine B.L. et al. Naive and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implications for transmission and pathogenesis. J. Virol. 72:1998;8273-8280.
21. Unutmaz D., Littman D.R. Expression pattern of HIV-1 coreceptors on T cells: implications for viral transmission and lymphocyte homing. Proc. Natl. Acad. Sci. USA. 94:1997;1615-1618.
22. + cells expanded from infected lymph nodes. AIDS Res. Hum. Retrovir. 14:1998;643-649.
23. Rowland-Jones S.L. Survival with HIV infection: good luck or good breeding? Trends Genet. 14:1998;343-345.
24. Spina C.A., Prince H.E. et al. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J. Clin. Invest. 99:1997;1774-1785.
25. Böhler T., Nedel S. et al. CD95-induced apoptosis contributes to loss of primed/memory but not resting/naive T cells in children infected with human immunodeficiency virus type 1. Pediatr. Res. 41:1997;878-885.
26. Gutheil W.G., Subramanyam M. et al. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc. Natl. Acad. Sci. USA. 91:1994;6594-6598.
27. Blanco J., Marié I. et al. Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26. Exp. Cell Res. 225:1996;102-111.
28. Smith R.E., Talhouk J.W. et al. The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. AIDS Res. Hum. Retrovir. 14:1998;851-868.
29. Valenzuela A., Blanco J. et al. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J. Immunol. 158:1997;3721-3729.
30. Franco R., Valenzuela A. et al. Enzymatic and extraenzymatic role of ecto-denosine deaminase in lymphocytes. Immunol. Rev. 161:1998;27-42.
31. Feito M.J., Bragardo M. et al. gp120s Derived from four syncytium-inducing HIV-1 strains induce different patterns of CD4 association with lymphocyte surface molecules. Int. Immunol. 9:1997;1141-1147.
32. Dalgleish A.G., Beverly P.C.L. et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312:1984;763-767.
33. Klatzmann D., Champagne E. et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 312:1984;767-768.
34. + cells. Science. 262:1993;2045-2050.
35. Feng Y., Broder C.C. et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science. 272:1996;872-877.
36. Alkhatib G., Combadiere C. et al. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
37. Deng H., Liu R. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
38. Dragic T., Litwin V. et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
39. Choe H., Farzan M. et al. The α-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
40. Bleul C.C., Farzan M. et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 382:1996;829-833.
41. Oberlin E., Amara A. et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 382:1996;833-835.
42. Doranz B.J., Rucker J. et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 85:1996;1149-1158.
43. Liao F., Alkhatib G. et al. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 185:1997;2015-2023.
44. Rollins B.J. Chemokines. Blood. 90:1997;909-928.
45. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. New Engl. J. Med. 338:1998;436-445.
46. Ward S.G., Bacon K. et al. Chemokines and T lymphocytes: more than an attraction. Immunity. 9:1998;1-11.
47. Ward S.G., Westwick J. Chemokines: understanding their role in T-lymphocyte biology. Biochem. J. 333:1998;457-470.
48. + T cells. Science. 270:1995;1811-1815.
49. Oravecz T., Pall M. et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186:1997;1865-1872.
50. Proost P., Meester I.D. et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV - conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. 273:1998;7222-7227.
51. Iwata S, Yamaguchi N, et al. 1999. CD26/DPPIV differentially regulates the chemotaxis of T cells and monocytes toward RANTES - possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999;11:417-426.
52. Struyf S., Meester I.D. et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 28:1998;1262-1271.
53. Hadida F., Vieillard V. et al. HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J. Exp. Med. 188:1998;609-614.
54. Shirozu M., Nakao T. et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 28:1995;495-500.
55. Shioda T., Kato H. et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl. Acad. Sci. USA. 95:1998;6331-6336.
56. Ohtsuki T., Hosono O. et al. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1α by CD26/dipeptidyl peptidase IV. FEBS Lett. 431:1998;236-240.
57. Proost P., Struyf S. et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1α FEBS Lett. 432:1998;73-76.
58. Crump M.P., Gong J.-H. et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16:1997;6996-7007.
59. Struyf S., Proost P. et al. Enhanced anti-HIV activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J. Immunol. 161:1998;2672-2675.
60. Pal R., Garzino-Demo A. et al. Inhibition of HIV-1 infection by the β-chemokine MDC. Science. 278:1997;695-698.
61. Lee B., Rucker J. et al. chemokine MDC and HIV-1 infection. Science. 281:1998;487a.
62. Kim J.J., Nottingham L.K. et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J. Clin. Invest. 102:1998;1112-1124.